Hematology

In this video, Brittany Watson, MD, MPH, FAAFP, DABOM and Joseph Mikhael, MD, MEd, FRCPC, FACP, discuss the role of primary care in the early recognition and diagnosis of multiple myeloma, including the...

Primary care physicians can help identify previously unrecognized hemophilia B, respond appropriately to bleeding and procedural risks, reinforce hematology-directed treatment plans, and support patients...

In the double-blind EPCAT III RCT, aspirin alone was noninferior to 5 days of rivaroxaban followed by aspirin for preventing symptomatic VTE after total hip or knee arthroplasty, with no clinically relevant...

Final phase 3 results assessed 5-year efficacy and safety of etranacogene dezaparvovec in adults with hemophilia B.

July 2026 included several FDA drug and biologic approvals across a range of therapeutic areas. This timeline highlights the key alerts our publication covered throughout the month, giving readers a quick,...

The FDA approved subcutaneous isatuximab-irfc (Sarclisa Escena, Sanofi-Aventis US LLC) for multiple myeloma treatment regimens across relapsed, refractory, and newly diagnosed disease settings.

The FDA expanded approval of exagamglogene autotemcel (Casgevy) for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia. ...

A phase 3 trial evaluated weekly marstacimab prophylaxis in adolescents and adults with hemophilia A or B with inhibitors.

The FDA approval expands the use of marstacimab-hncq (Hympavzi; Pfizer Inc.) for routine prophylaxis to prevent or reduce bleeding episodes in additional pediatric and inhibitor-positive hemophilia A and B...

In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.